Diagnostics Rapidly Gain Ground in Infectious Diseases Sector
By LabMedica International staff writers Posted on 22 Dec 2014 |
According to a new Frost & Sullivan (Mountain View, CA, USA) analysis, convergence of immunological and molecular tests will help meet growing needs for infectious disease (ID) diagnostics. Although these tests remain expensive, their efficiency and accuracy strengthen their use case.
Frost & Sullivan’s new report “Analysis of the Global Infectious Disease Diagnostics Market” finds the market earned USD 7.91 billion revenue in 2013 and estimates it to reach USD 12.77 billion in 2018. Hepatitis B, hepatitis C, tuberculosis, and sepsis tests are predicted to be the major revenue generators.
The market will continue to develop as unmet technological needs lead to the creation of faster, more capable platforms. Molecular ID-diagnostics is growing fastest, clocking a compound annual growth of 15.3%. “Immunodiagnostics is another segment that continues to expand rapidly owing to cost-effective tests as well as the prevalence of hospital-acquired infections like sepsis and MRSA,” said Frost & Sullivan life sciences industry analyst Aish Vivekanandan, “Molecular methods and immunodiagnostics are expected to complement each other as the need for accurate and rapid diagnostic tests rises.”
Unique disease outbreaks across the globe are further escalating the demand for screening, spurring the ID diagnostic market. While decentralized and rapid tests are a growing trend in the developed world, stringent regulations complicate product development and marketing, and high costs affect the market in developing countries. Another challenge is low product awareness across regions. Companies must invest in clinical studies to prove the efficacy of their products and raise awareness among evidence-driven consumers, especially in the clinical field.
“Many participants are focusing their research on top industry requirements such as product automation, rapidity, specificity, and accuracy,” noted Vivekanandan, “Companies are also striving to expand the scope of diseases their products cover in order to establish their foothold in the global ID diagnostics market.”
The new report is part of Frost & Sullivan’s Life Sciences Growth Partnership Service program. Related studies include: “Global in Vitro Diagnostics Market,” “US Hematology Diagnostics Market,” “Global Next-generation Sequencing Market,” and “Western European Companion Diagnostics Market.” All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
Related Links:
Frost & Sullivan
Analysis of the Global Infectious Disease Diagnostics Market report
Life Sciences Growth Partnership Service program
Frost & Sullivan’s new report “Analysis of the Global Infectious Disease Diagnostics Market” finds the market earned USD 7.91 billion revenue in 2013 and estimates it to reach USD 12.77 billion in 2018. Hepatitis B, hepatitis C, tuberculosis, and sepsis tests are predicted to be the major revenue generators.
The market will continue to develop as unmet technological needs lead to the creation of faster, more capable platforms. Molecular ID-diagnostics is growing fastest, clocking a compound annual growth of 15.3%. “Immunodiagnostics is another segment that continues to expand rapidly owing to cost-effective tests as well as the prevalence of hospital-acquired infections like sepsis and MRSA,” said Frost & Sullivan life sciences industry analyst Aish Vivekanandan, “Molecular methods and immunodiagnostics are expected to complement each other as the need for accurate and rapid diagnostic tests rises.”
Unique disease outbreaks across the globe are further escalating the demand for screening, spurring the ID diagnostic market. While decentralized and rapid tests are a growing trend in the developed world, stringent regulations complicate product development and marketing, and high costs affect the market in developing countries. Another challenge is low product awareness across regions. Companies must invest in clinical studies to prove the efficacy of their products and raise awareness among evidence-driven consumers, especially in the clinical field.
“Many participants are focusing their research on top industry requirements such as product automation, rapidity, specificity, and accuracy,” noted Vivekanandan, “Companies are also striving to expand the scope of diseases their products cover in order to establish their foothold in the global ID diagnostics market.”
The new report is part of Frost & Sullivan’s Life Sciences Growth Partnership Service program. Related studies include: “Global in Vitro Diagnostics Market,” “US Hematology Diagnostics Market,” “Global Next-generation Sequencing Market,” and “Western European Companion Diagnostics Market.” All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
Related Links:
Frost & Sullivan
Analysis of the Global Infectious Disease Diagnostics Market report
Life Sciences Growth Partnership Service program
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance